<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>MicroRNAs (miRNAs) are small non-coding <z:chebi fb="40" ids="33697">RNAs</z:chebi> that regulate gene expression by binding to complementary sequences in <z:chebi fb="2" ids="33699">mRNAs</z:chebi> encoding downstream target genes </plain></SENT>
<SENT sid="1" pm="."><plain>A large variety of cellular processes, including differentiation, development, <z:mpath ids='MPATH_3'>apoptosis</z:mpath> and cell cycle progression, are dependent on miRNA-mediated suppression of gene expression for their regulation </plain></SENT>
<SENT sid="2" pm="."><plain>As such, it is unsurprising that these small <z:chebi fb="40" ids="33697">RNA</z:chebi> molecules are associated with signaling networks that are often altered in various diseases, including many <z:e sem="disease" ids="C0376544" disease_type="Neoplastic Process" abbrv="">blood cancers</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>One such network is the nuclear factor-κB (NF-κB) pathways that universally stimulate transcription of proteins which generally promote cell survival, inhibit <z:mpath ids='MPATH_3'>apoptosis</z:mpath>, allow cellular growth, induce <z:mpath ids='MPATH_177'>angiogenesis</z:mpath> and generate many pro-<z:mp ids='MP_0001845'>inflammatory responses</z:mp> </plain></SENT>
<SENT sid="4" pm="."><plain>The NF-κB signalling pathway is often constitutively activated in blood cell <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> including <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>), <z:hpo ids='HP_0011009'>acute</z:hpo> <z:mpath ids='MPATH_342'>myeloid leukaemia</z:mpath> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>), <z:hpo ids='HP_0011009'>acute</z:hpo> lymphocytic <z:mpath ids='MPATH_336'>leukaemia</z:mpath> (ALL), <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:mpath ids='MPATH_342'>myeloid leukaemia</z:mpath> (<z:mp ids='MP_0005481'>CML</z:mp>), <z:hpo ids='HP_0011010'>chronic</z:hpo> lymphocytic <z:mpath ids='MPATH_336'>leukaemia</z:mpath> (CLL), <z:hpo ids='HP_0002665'>lymphomas</z:hpo> and in <z:hpo ids='HP_0006775'>multiple myeloma</z:hpo> (MM) </plain></SENT>
<SENT sid="5" pm="."><plain>This review focuses on the function of miRNAs that directly target NF-κB signaling cascade </plain></SENT>
<SENT sid="6" pm="."><plain>Recent findings that connect this pathway through various miRNA families to human <z:e sem="disease" ids="C0376544" disease_type="Neoplastic Process" abbrv="">blood cancers</z:e> are reviewed, and support for using miRNA-based therapy as a novel method to counteract this <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e>-promoting signalling event is discussed </plain></SENT>
</text></document>